Overview
Mesoblast’s leadership in the development and commercialization of allogeneic cellular medicines is based on its innovative technology platform, proprietary manufacturing processes and multiple Phase 3 assets.Our off-the-shelf product candidates target advanced stages of inflammatory diseases with high, unmet medical needs.
Three product candidates are being evaluated in late-stage development for approval by the United States Food and Drug Administration (“FDA”):
• We have filed a Biologics License Application (“BLA”) to the FDA to seek approval of remestemcel-L for steroid-refractory acute graft versus host disease (“SR-aGVHD”) in children under the brand name RYONCILTM (“RYONCIL”);
• REVASCOR (MPC-150-IM) for advanced heart failure in ongoing Phase 3 clinical trials; and
• MPC-06-ID for chronic low back pain due to degenerative disc disease in ongoing Phase 3 clinical trials.
- Forums
- ASX - By Stock
- MSB
- Ann: Third Quarter Financial Results on Form 6-K
Ann: Third Quarter Financial Results on Form 6-K, page-3
-
- There are more pages in this discussion • 42 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
92.5¢ |
Change
-0.020(2.12%) |
Mkt cap ! $1.056B |
Open | High | Low | Value | Volume |
93.0¢ | 93.5¢ | 92.0¢ | $2.103M | 2.270M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
11 | 106422 | 92.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
93.0¢ | 59027 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 11 | 0.940 |
4 | 73143 | 0.935 |
1 | 1075 | 0.930 |
7 | 75048 | 0.925 |
14 | 110978 | 0.920 |
Price($) | Vol. | No. |
---|---|---|
0.880 | 8931 | 1 |
0.930 | 33508 | 3 |
0.935 | 20000 | 1 |
0.940 | 30800 | 1 |
0.945 | 20000 | 1 |
Last trade - 16.10pm 09/09/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |